Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Insulet Corporation, 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Insulet Corporation May 22, 202598.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 20, 2026 | Insulet Corporation | Grant or award | +1,660 | — | — |
| Jun 16, 2025 | Maravai LifeSciences Holdings Inc. | Grant or award | +89,139 | $2.16 | $192,540 |
| May 22, 2025 | Insulet Corporation | Grant or award | +778 | — | — |
| May 13, 2025 | Insulet Corporation | Option exercise | +5,235 | $28.87 | $151,134 |
| May 13, 2025 | Insulet Corporation | Open-market sale | −5,235 | $317.54 | $1,662,322 |
| Sep 11, 2024 | Insulet Corporation | Option exercise | +7,628 | $29.87 | $227,848 |
| Sep 11, 2024 | Insulet Corporation | Open-market sale | −7,628 | $225.26 | $1,718,283 |
| May 23, 2024 | Maravai LifeSciences Holdings Inc. | Grant or award | +20,645 | $10.78 | $222,553 |
| May 22, 2024 | Insulet Corporation | Grant or award | +1,380 | — | — |
| May 13, 2024 | Editas Medicine Inc. | Open-market purchase | +45,000 | $5.64 | $253,800 |
| Jul 17, 2023 | Maravai LifeSciences Holdings Inc. | Grant or award | +24,000 | — | — |
| May 23, 2023 | Insulet Corporation | Grant or award | +843 | — | — |
Questions about Jessica Hopfield
What boards is Jessica Hopfield on?
Jessica Hopfield sits on the boards of Editas Medicine Inc., Insulet Corporation and Maravai LifeSciences Holdings Inc.
How long has Jessica Hopfield served on boards?
Our records show at least 10 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.